AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label nonrandomized multi-center study designed to evaluate the effect of
AP23573 in patients with recurrent or persistent endometrial cancer. The primary objective is
to assess the efficacy of AP23573 in patients with recurrent or persistent endometrial cancer
when administered once daily for 5 consecutive days (QDx5) every two weeks at a dose of 12.5
mg/day.